Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies Petra El Khoury Sandy Elbitar Marianne Abifadel Current Atherosclerosis Reports (2017) ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

For whichever PCSK9 we choose, we get an additional 50% to 60% LDL reduction by using these therapies. So, they work. They lower events. Both trials with PCSK9 inhibitors lowered events by about 15%.

PCSK9’s story begins a dozen years ago when researchers led by Nabil G. Seidah of the Clinical Research Institute of Montreal discovered an unusual protein (Proc. Natl. Acad. Sci. USA 2003, DOI ...

Anti-PCSK9 antibodies are the jewel in the crown of modern genomic medicine, illustrating what many hope will be a paradigm for future drug discovery.

The PCSK9 inhibitors pose a similar, but in many ways more compelling and complex, set of problems. Their target, hyperlipidemia, is one of the most prevalent conditions in the developed world.

A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year ...